» Articles » PMID: 23409726

Study Design of DIACORE (DIAbetes COhoRtE) - a Cohort Study of Patients with Diabetes Mellitus Type 2

Overview
Journal BMC Med Genet
Publisher Biomed Central
Specialty Genetics
Date 2013 Feb 16
PMID 23409726
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Diabetes mellitus type 2 (DM2) is highly associated with increased risk for chronic kidney disease (CKD), end stage renal disease (ESRD) and cardiovascular morbidity. Epidemiological and genetic studies generate hypotheses for innovative strategies in DM2 management by unravelling novel mechanisms of diabetes complications, which is essential for future intervention trials. We have thus initiated the DIAbetes COhoRtE study (DIACORE).

Methods: DIACORE is a prospective cohort study aiming to recruit 6000 patients of self-reported Caucasian ethnicity with prevalent DM2 for at least 10 years of follow-up. Study visits are performed in University-based recruiting clinics in Germany using standard operating procedures. All prevalent DM2 patients in outpatient clinics surrounding the recruiting centers are invited to participate. At baseline and at each 2-year follow-up examination, patients are subjected to a core phenotyping protocol. This includes a standardized online questionnaire and physical examination to determine incident micro- and macrovascular DM2 complications, malignancy and hospitalization, with a primary focus on renal events. Confirmatory outcome information is requested from patient records. Blood samples are obtained for a centrally analyzed standard laboratory panel and for biobanking of aliquots of serum, plasma, urine, mRNA and DNA for future scientific use. A subset of the cohort is subjected to extended phenotyping, e.g. sleep apnea screening, skin autofluorescence measurement, non-mydriatic retinal photography and non-invasive determination of arterial stiffness.

Discussion: DIACORE will enable the prospective evaluation of factors involved in DM2 complication pathogenesis using high-throughput technologies in biosamples and genetic epidemiological studies.

Citing Articles

Nocturnal hypoxemic burden and micro- and macrovascular disease in patients with type 2 diabetes.

Driendl S, Stadler S, Arzt M, Zeman F, Heid I, Baumert M Cardiovasc Diabetol. 2024; 23(1):195.

PMID: 38844945 PMC: 11157751. DOI: 10.1186/s12933-024-02289-w.


Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease.

Gregorich M, Kammer M, Heinzel A, Boger C, Eckardt K, Heerspink H JAMA Netw Open. 2023; 6(4):e231870.

PMID: 37017968 PMC: 10077108. DOI: 10.1001/jamanetworkopen.2023.1870.


[High patient unawareness for chronic kidney disease even in later stages - but why is it more frequent in women than in men?].

Stolpe S, Scholz C, Stang A, Boger C, Jung B, Kowall B Dtsch Med Wochenschr. 2022; 147(17):e70-e81.

PMID: 35926520 PMC: 9420553. DOI: 10.1055/a-1819-0870.


Long-Term Weight Change and Glycemic Control in Patients With Type 2 Diabetes Mellitus and Treated vs. Untreated Sleep-Disordered Breathing-Analysis From the DIAbetes COhoRtE.

Schaller L, Arzt M, Jung B, Boger C, Heid I, Stadler S Front Neurol. 2021; 12:745049.

PMID: 34925210 PMC: 8675635. DOI: 10.3389/fneur.2021.745049.


Clinical Significance of Non-invasive Skin Autofluorescence Measurement in Patients with Diabetes: A Systematic Review and Meta-analysis.

Hosseini M, Razavi Z, Ehsani A, Firooz A, Afazeli S EClinicalMedicine. 2021; 42:101194.

PMID: 34841236 PMC: 8605318. DOI: 10.1016/j.eclinm.2021.101194.


References
1.
Perkins B, Ficociello L, Ostrander B, Silva K, Weinberg J, Warram J . Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007; 18(4):1353-61. DOI: 10.1681/ASN.2006080872. View

2.
Kottgen A, Hwang S, Larson M, Van Eyk J, Fu Q, Benjamin E . Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol. 2009; 21(2):337-44. PMC: 2834540. DOI: 10.1681/ASN.2009070725. View

3.
Igo Jr R, Iyengar S, Nicholas S, Goddard K, Langefeld C, Hanson R . Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol. 2011; 33(5):381-9. PMC: 3078269. DOI: 10.1159/000326763. View

4.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

5.
Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60. DOI: 10.1056/NEJMoa011303. View